Pds Biotechnology Corp (PDSB)

$2.64

+0.09

(+3.53%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Pds Biotechnology Corp

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 78.5% return, outperforming this stock by 130.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.7% return, outperforming this stock by 323.7%

Performance

  • $2.53
    $2.66
    $2.64
    downward going graph

    4.17%

    Downside

    Day's Volatility :4.89%

    Upside

    0.75%

    downward going graph
  • $2.53
    $6.85
    $2.64
    downward going graph

    4.17%

    Downside

    52 Weeks Volatility :63.07%

    Upside

    61.46%

    downward going graph

Returns

PeriodPds Biotechnology CorpSector (Health Care)Index (Russel 2000)
3 Months
-44.19%
0.9%
0.0%
6 Months
-48.54%
8.7%
0.0%
1 Year
-51.56%
11.2%
0.0%
3 Years
-75.96%
17.9%
-23.2%

Highlights

Market Capitalization
93.5M
Book Value
$1.01
Earnings Per Share (EPS)
-1.37
Wall Street Target Price
12.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-39.76%
Return On Equity TTM
-112.25%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-43.7M
Diluted Eps TTM
-1.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.3
EPS Estimate Next Year
-1.23
EPS Estimate Current Quarter
-0.37
EPS Estimate Next Quarter
-0.36

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Pds Biotechnology Corp(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 354.55%

Current $2.64
Target $12.00

Technicals Summary

Sell

Neutral

Buy

Pds Biotechnology Corp is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pds Biotechnology Corp
Pds Biotechnology Corp
-15.38%
-48.54%
-51.56%
-75.96%
-53.27%
Moderna, Inc.
Moderna, Inc.
-18.66%
37.06%
12.57%
-37.09%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.4%
23.97%
35.06%
98.78%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
4.71%
38.25%
78.49%
247.73%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.97%
14.98%
35.07%
149.95%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pds Biotechnology Corp
Pds Biotechnology Corp
NA
NA
NA
-1.3
-1.12
-0.4
NA
1.01
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pds Biotechnology Corp
Pds Biotechnology Corp
Buy
$93.5M
-53.27%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • BlackRock Inc

    5.09%
  • Vanguard Group Inc

    4.33%
  • Geode Capital Management, LLC

    1.78%
  • State Street Corporation

    1.52%
  • Integrys Wealth Advisors LLC

    0.97%
  • Renaissance Technologies Corp

    0.97%

Company Information

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati

Organization
Pds Biotechnology Corp
Employees
25
CEO
Dr. Frank K. Bedu-Addo Ph.D.
Industry
Biotechnology

FAQs